Investing.comQwen · 实盘不做把握 1/10不做原因:标的无直接敞口
北京时间·🕒 发布 20:36:44·⟳ 抓取 20:37:47 +1m03s·⚡ 决策 08-27 20:40:00 +2m13s·61.4 天前
Valion Bio宣布1:25缩股以维持纳斯达克上市资格，8月31日生效
缩股（reverse split）是纯程序性合规动作，不改变企业价值和基本面。经验明确指出'拆并股不改变企业价值'。该事件8月14日已获股东批准，属于程序性落地的明牌，无预期差。微型股（股价<$1）流动性极差，无论多空方向均无法有效执行。不存在可交易的因果敞口。
📄 原文Investing.com↗ 原文
Valion Bio announces 1-for-25 reverse stock split
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook SAN ANTONIO - Valion Bio, Inc. (NASDAQ:V…
不做 Valion Bio（VBIO.US）
缩股是纯程序性合规动作，不改变企业价值或基本面方向；8月14日已获股东批准属明牌落地；微型股（<$1）流动性极差无法有效执行；无预期差、无因果敞口、无方向性edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Valion Bio因股价连续30日低于$1.00被纳斯达克通知，实施1:25缩股以恢复合规。缩股不改变企业价值、收入、利润或股东权益，是纯机械性合规动作。股东8月14日已批准，非新增信息。标的为微型股，流动性极差。经验确认拆并股不创造基本面催化，把握度应锚定预期差而非事件名义——此处预期差为零。结论：不做。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:缩股不改变企业价值，无方向性交易逻辑，先例研究不改变结论
方向:无可用先例
涨幅量级:无
形态:无
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 1,146 ms
{ - search_processed_events 成功 stock_tools HTTP · 2,106 ms
{"result": "search_processed_events:agent query=`valion bio reverse stock split | vbio 1-for-25 reverse split nasdaq compliance`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.4/72 小时、11367 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - search_case_library 成功 stock_tools HTTP · 235 ms
{"result": "search_case_library「VBIO.US」—— 与这些标的相关的自家决策案例(本页 2 条,该标的全历史相关记录共 2 条；ENTER 只按该标的自己的腿统计):\n◆ VBIO.US：相关历史决策 2 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 2 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-07-27 UTC 不做 — Ukraine Ministry of Heal
原文全文
展开原文 · 2,328 字
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook
SAN ANTONIO - Valion Bio, Inc. (NASDAQ:VBIO) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, effective August 31, 2026, at 12:01 AM Eastern Time.
The reverse stock split aims to bring the company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Stockholders approved the reverse stock split at a special meeting held on August 14, 2026.
The company’s common stock is expected to begin trading on a split-adjusted basis when markets open on August 31, 2026, under the current trading symbol "VBIO." The new CUSIP for the company’s common stock following the reverse split will be 918942202.
Every 25 shares of common stock issued and outstanding or held as treasury stock on the effective date will be automatically reclassified into one new share. Proportionate adjustments will be made to conversion and exercise prices and the number of shares underlying the company’s preferred stock, outstanding warrants, equity awards and options.
The reverse stock split will not affect the number of shares of preferred stock issued and outstanding, the number of shares authorized under the company’s charter, or the par value of the company’s stock. Each stockholder’s percentage ownership interest and proportional voting power will remain materially unchanged, except for changes resulting from rounding fractional shares into whole shares.
No fractional shares will be issued. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
Odyssey Transfer and Trust Company is acting as the exchange agent for the reverse stock split. Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take action.
The company received notification from Nasdaq on March 19, 2026, that its common stock’s closing bid price was below $1.00 per share for 30 consecutive trading days. Nasdaq provided the company until September 15, 2026, to regain compliance.
This information is based on a press release statement from Valion Bio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN ANTONIO - Valion Bio, Inc. (NASDAQ:VBIO) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the company’s common stock, effective August 31, 2026, at 12:01 AM Eastern Time.
The reverse stock split aims to bring the company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Stockholders approved the reverse stock split at a special meeting held on August 14, 2026.
The company’s common stock is expected to begin trading on a split-adjusted basis when markets open on August 31, 2026, under the current trading symbol "VBIO." The new CUSIP for the company’s common stock following the reverse split will be 918942202.
Every 25 shares of common stock issued and outstanding or held as treasury stock on the effective date will be automatically reclassified into one new share. Proportionate adjustments will be made to conversion and exercise prices and the number of shares underlying the company’s preferred stock, outstanding warrants, equity awards and options.
The reverse stock split will not affect the number of shares of preferred stock issued and outstanding, the number of shares authorized under the company’s charter, or the par value of the company’s stock. Each stockholder’s percentage ownership interest and proportional voting power will remain materially unchanged, except for changes resulting from rounding fractional shares into whole shares.
No fractional shares will be issued. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
Odyssey Transfer and Trust Company is acting as the exchange agent for the reverse stock split. Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take action.
The company received notification from Nasdaq on March 19, 2026, that its common stock’s closing bid price was below $1.00 per share for 30 consecutive trading days. Nasdaq provided the company until September 15, 2026, to regain compliance.
This information is based on a press release statement from Valion Bio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。